Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7676129 | 0.82 | AR (0.33) | ARTRPA1 | |
| SCHEMBL5128847 | 0.82 | AR (0.33) | ARTRPA1 | |
| SCHEMBL5114972 | 0.81 | AR (0.49) | ARTRPA1 | |
| SCHEMBL5114827 | 0.79 | AR (0.53) | ARTRPA1 | |
| SCHEMBL5114835 | 0.79 | AR (0.53) | ARTRPA1 | |
| SCHEMBL5120211 | 0.78 | AR (0.31) | AR | |
| SCHEMBL5494359 | 0.76 | AR (0.40) | ARTRPA1 | |
| SCHEMBL5118678 | 0.76 | AR (0.40) | ARTRPA1 | |
| SCHEMBL5128200 | 0.75 | AR (0.39) | AR | |
| SCHEMBL5122002 | 0.75 | AR (0.55) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | HIGUCHI ROBERT I | 2008-12-04 | — | — | US | disclosed |
| US-7214690-B2 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885TRPA1 1424/4885 |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885TRPA1 1415/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885TRPA1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.